Association of progression-free survival with patient-reported outcomes and survival: Results from a randomised phase 3 trial of panitumumab

S. Siena; M. Peeters; E. Van Cutsem; Y. Humblet; P. Conte; E. Bajetta; D. Comandini; G. Bodoky; G. Van Hazel; T. Salek; M. Wolf; G. Devercelli; M. Woolley; R. G. Amado

doi:10.1038/sj.bjc.6604053

Association of progression-free survival with patient-reported outcomes and survival: Results from a randomised phase 3 trial of panitumumab

S. Siena, M. Peeters, E. Van Cutsem, Y. Humblet, P. Conte, E. Bajetta, D. Comandini, G. Bodoky, G. Van Hazel, T. Salek, M. Wolf, G. Devercelli, M. Woolley, R. G. Amado

Istituto Oncologico Veneto

Research output: Contribution to journal › Article

Abstract

In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). This analysis characterises the association of PFS with CRC symptoms, health-related quality of life (HRQoL), and overall survival (OS). CRC symptoms (NCCN/FACT CRC symptom index, FCSI) and HRQoL (EQ-5D) were assessed for 207 panitumumab patients and 184 best supportive care (BSC) patients who had at least one post-baseline patient-reported outcome (PRO) assessment. Patients alive at week 8 were included in the PRO and OS analyses and categorised by their week 8 progression status as follows: no progressive disease (no PD; best response of at least stable disease) vs progressive disease (PD). Standard imputation methods were used to assign missing values. Significantly more patients were progression free at weeks 8-24 with panitumumab vs BSC. After excluding responders, a significant difference in PFS remained favouring panitumumab (HR=0.63, 95% CI=0.52-0.77; P

Original language	English
Pages (from-to)	1469-1474
Number of pages	6
Journal	British Journal of Cancer
Volume	97
Issue number	11
DOIs	https://doi.org/10.1038/sj.bjc.6604053
Publication status	Published - Dec 3 2007

Keywords

Disease progression
Improvement
Panitumumab
Patient-reported outcomes
Quality of life
Symptom

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1038/sj.bjc.6604053

Fingerprint Dive into the research topics of 'Association of progression-free survival with patient-reported outcomes and survival: Results from a randomised phase 3 trial of panitumumab'. Together they form a unique fingerprint.

Cite this

Siena, S., Peeters, M., Van Cutsem, E., Humblet, Y., Conte, P., Bajetta, E., Comandini, D., Bodoky, G., Van Hazel, G., Salek, T., Wolf, M., Devercelli, G., Woolley, M., & Amado, R. G. (2007). Association of progression-free survival with patient-reported outcomes and survival: Results from a randomised phase 3 trial of panitumumab. British Journal of Cancer, 97(11), 1469-1474. https://doi.org/10.1038/sj.bjc.6604053

Association of progression-free survival with patient-reported outcomes and survival : Results from a randomised phase 3 trial of panitumumab. / Siena, S.; Peeters, M.; Van Cutsem, E.; Humblet, Y.; Conte, P.; Bajetta, E.; Comandini, D.; Bodoky, G.; Van Hazel, G.; Salek, T.; Wolf, M.; Devercelli, G.; Woolley, M.; Amado, R. G.

In: British Journal of Cancer, Vol. 97, No. 11, 03.12.2007, p. 1469-1474.

Research output: Contribution to journal › Article

Siena, S, Peeters, M, Van Cutsem, E, Humblet, Y, Conte, P, Bajetta, E, Comandini, D, Bodoky, G, Van Hazel, G, Salek, T, Wolf, M, Devercelli, G, Woolley, M & Amado, RG 2007, 'Association of progression-free survival with patient-reported outcomes and survival: Results from a randomised phase 3 trial of panitumumab', British Journal of Cancer, vol. 97, no. 11, pp. 1469-1474. https://doi.org/10.1038/sj.bjc.6604053

Siena, S. ; Peeters, M. ; Van Cutsem, E. ; Humblet, Y. ; Conte, P. ; Bajetta, E. ; Comandini, D. ; Bodoky, G. ; Van Hazel, G. ; Salek, T. ; Wolf, M. ; Devercelli, G. ; Woolley, M. ; Amado, R. G. / Association of progression-free survival with patient-reported outcomes and survival : Results from a randomised phase 3 trial of panitumumab. In: British Journal of Cancer. 2007 ; Vol. 97, No. 11. pp. 1469-1474.

@article{9ade82bf72f149a78b9d33ff15508680,

title = "Association of progression-free survival with patient-reported outcomes and survival: Results from a randomised phase 3 trial of panitumumab",

abstract = "In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). This analysis characterises the association of PFS with CRC symptoms, health-related quality of life (HRQoL), and overall survival (OS). CRC symptoms (NCCN/FACT CRC symptom index, FCSI) and HRQoL (EQ-5D) were assessed for 207 panitumumab patients and 184 best supportive care (BSC) patients who had at least one post-baseline patient-reported outcome (PRO) assessment. Patients alive at week 8 were included in the PRO and OS analyses and categorised by their week 8 progression status as follows: no progressive disease (no PD; best response of at least stable disease) vs progressive disease (PD). Standard imputation methods were used to assign missing values. Significantly more patients were progression free at weeks 8-24 with panitumumab vs BSC. After excluding responders, a significant difference in PFS remained favouring panitumumab (HR=0.63, 95% CI=0.52-0.77; P",

keywords = "Disease progression, Improvement, Panitumumab, Patient-reported outcomes, Quality of life, Symptom",

author = "S. Siena and M. Peeters and {Van Cutsem}, E. and Y. Humblet and P. Conte and E. Bajetta and D. Comandini and G. Bodoky and {Van Hazel}, G. and T. Salek and M. Wolf and G. Devercelli and M. Woolley and Amado, {R. G.}",

year = "2007",

month = dec,

day = "3",

doi = "10.1038/sj.bjc.6604053",

language = "English",

volume = "97",

pages = "1469--1474",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Association of progression-free survival with patient-reported outcomes and survival

T2 - Results from a randomised phase 3 trial of panitumumab

AU - Siena, S.

AU - Peeters, M.

AU - Van Cutsem, E.

AU - Humblet, Y.

AU - Conte, P.

AU - Bajetta, E.

AU - Comandini, D.

AU - Bodoky, G.

AU - Van Hazel, G.

AU - Salek, T.

AU - Wolf, M.

AU - Devercelli, G.

AU - Woolley, M.

AU - Amado, R. G.

PY - 2007/12/3

Y1 - 2007/12/3

N2 - In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). This analysis characterises the association of PFS with CRC symptoms, health-related quality of life (HRQoL), and overall survival (OS). CRC symptoms (NCCN/FACT CRC symptom index, FCSI) and HRQoL (EQ-5D) were assessed for 207 panitumumab patients and 184 best supportive care (BSC) patients who had at least one post-baseline patient-reported outcome (PRO) assessment. Patients alive at week 8 were included in the PRO and OS analyses and categorised by their week 8 progression status as follows: no progressive disease (no PD; best response of at least stable disease) vs progressive disease (PD). Standard imputation methods were used to assign missing values. Significantly more patients were progression free at weeks 8-24 with panitumumab vs BSC. After excluding responders, a significant difference in PFS remained favouring panitumumab (HR=0.63, 95% CI=0.52-0.77; P

AB - In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). This analysis characterises the association of PFS with CRC symptoms, health-related quality of life (HRQoL), and overall survival (OS). CRC symptoms (NCCN/FACT CRC symptom index, FCSI) and HRQoL (EQ-5D) were assessed for 207 panitumumab patients and 184 best supportive care (BSC) patients who had at least one post-baseline patient-reported outcome (PRO) assessment. Patients alive at week 8 were included in the PRO and OS analyses and categorised by their week 8 progression status as follows: no progressive disease (no PD; best response of at least stable disease) vs progressive disease (PD). Standard imputation methods were used to assign missing values. Significantly more patients were progression free at weeks 8-24 with panitumumab vs BSC. After excluding responders, a significant difference in PFS remained favouring panitumumab (HR=0.63, 95% CI=0.52-0.77; P

KW - Disease progression

KW - Improvement

KW - Panitumumab

KW - Patient-reported outcomes

KW - Quality of life

KW - Symptom

UR - http://www.scopus.com/inward/record.url?scp=36448973509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448973509&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604053

DO - 10.1038/sj.bjc.6604053

M3 - Article

C2 - 18040272

AN - SCOPUS:36448973509

VL - 97

SP - 1469

EP - 1474

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -